Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pioneering Human Protein Atlas Project Achieves a Major Milestone

Published: Thursday, March 20, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
Project leverages Luminex's xMAP® technology for biobank profiling research.

Luminex Corporation has announced that xMAP® Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project.

In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.

The goal of the Human Protein Atlas project is to explore the entirety of the human proteome using antibody-based proteomics. This pioneering project leverages Luminex's xMAP Technology for biobank research of body fluids.

The high-throughput biomarker screening approach combines Luminex technology with several thousand antibodies through multiplexed screening of over 380 targets per well per run.

"We are very excited to be part of this revolutionary systematic exploration of the next frontier in human biology, the human proteome," said Patrick Balthrop president and CEO of Luminex.

Balthrop continued, "This project goes beyond the genome to advance the understanding of human disease and cell function. We look forward to continuing to partner on these groundbreaking projects that advance research by developing products that help scientists make discoveries, and advance science to ultimately improve the health and quality of life for all."

"In addition to our own research, we collaborate with partners to identify interesting candidate biomarkers for a wide range of diseases," said Jochen Schwenk, Ph.D., Associate Professor of Translational Proteomics at KTH Royal Institute of Technology and facility manager at the Science for Life Laboratory.

Schwenk continued, "The Luminex xMAP Technology has made it possible for us to perform truly flexible and very high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples. We then develop downstream biomarker validation assays on the same xMAP Technology."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Receives FDA Clearance for Aries M1 System
Company has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System.
Thursday, July 07, 2016
Luminex Completes Acquisition of Nanosphere
The acquisition provides Luminex with Nanosphere's high-plex, low-throughput system to complement its existing molecular platforms.
Friday, July 01, 2016
Luminex Receives CE-IVD Mark
Company has announced that it has received CE-IVD mark for ARIES® Flu A/B & RSV Assay.
Thursday, June 02, 2016
Luminex to Acquire Nanosphere
Nanosphere to be acquired for $1.35 per share in an all cash transaction valued at approximately $58 million.
Monday, May 16, 2016
Luminex SYNCT Software Receives FDA Clearance, CE Mark
Company has announced that its SYNCT™ Software has received both U.S. FDA clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System.
Friday, April 15, 2016
Luminex Receives CE-IVD Mark for ARIES System
The ARIES® System and ARIES®HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Tuesday, March 22, 2016
Luminex, University of Sao Paulo Collaborate
Luminex Corporation has announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner,GenArraytion, Inc.
Monday, February 29, 2016
Luminex Corporation Announces Collaboration with University of Sao Paulo
Company has announced collaboration to validate a multi analyte zika virus detection panel for detect multiple disease agent.
Friday, February 26, 2016
Luminex Corporation Receives Medical Device License
Company has announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate for ARIES System and ARIES HSV 1&2 Assay.
Tuesday, February 23, 2016
Luminex and Bio-Techne Extend and Expand Partnership
Company expands global distribution of award-winning multiplexing instrumentation.
Friday, October 23, 2015
Luminex Receives FDA Clearance
Company has received clearance for ARIES® System and ARIES® HSV 1&2 Assay.
Thursday, October 08, 2015
Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
Company expects its FDA submission for the ARIES platform in the summer of 2015.
Tuesday, June 09, 2015
Luminex Corporation Reports First Quarter 2015 Results
Company announces financial and operating highlights.
Tuesday, May 12, 2015
Luminex Corporation Provides Updates on ARIES® Clinical Trials
Clinical trials initiated for ARIES® Clostridium difficile assay.
Friday, May 01, 2015
Luminex Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
Company plans to seek both FDA clearance and CE IVD marking this year.
Tuesday, March 31, 2015
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!